Keywords: Glaucoma treatments, Market forecasts, Frost & Sullivan

Vast market for glaucoma pharmaceuticals, as 50% of patients remain untreated, finds F&S

Article | 26 April 2012

Glaucoma is the second leading cause of blindness in the USA, presenting the glaucoma pharmaceuticals market with a significant opportunity ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in